80 related articles for article (PubMed ID: 6465093)
1. The value of secretory component (SC) immunoreactivity in diagnosis and prognosis of colorectal carcinomas.
Arends JW; Wiggers T; Thijs CT; Verstijnen C; Swaen GJ; Bosman FT
Am J Clin Pathol; 1984 Sep; 82(3):267-74. PubMed ID: 6465093
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of CEA immunoreactivity patterns in large bowel carcinoma tissue.
Wiggers T; Arends JW; Verstijnen C; Moerkerk PM; Bosman FT
Br J Cancer; 1986 Sep; 54(3):409-14. PubMed ID: 3756077
[TBL] [Abstract][Full Text] [Related]
3. The occurrence and clinicopathological significance of serotonin immunoreactive cells in large bowel carcinoma.
Arends JW; Wiggers T; Verstijnen K; Bosman FT
J Pathol; 1986 Jun; 149(2):97-102. PubMed ID: 3525789
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the secretory component as a prognostic variable in colorectal carcinoma.
Koretz K; Schlag P; Quentmeier A; Möller P
Int J Cancer; 1994 May; 57(3):365-70. PubMed ID: 8168997
[TBL] [Abstract][Full Text] [Related]
5. Endocrine cells in colorectal adenocarcinomas: incidence, hormone profile and prognostic relevance.
de Bruïne AP; Wiggers T; Beek C; Volovics A; von Meyenfeldt M; Arends JW; Bosman FT
Int J Cancer; 1993 Jul; 54(5):765-71. PubMed ID: 8100808
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal cancer-associated antigen (GICA) immunoreactivity in colorectal carcinoma in relation to patient survival.
Arends JW; Wiggers T; Verstijnen C; Hilgers J; Bosman FT
Int J Cancer; 1984 Aug; 34(2):193-6. PubMed ID: 6381331
[TBL] [Abstract][Full Text] [Related]
7. Adenosine deaminase complexing protein (ADCP) immunoreactivity in colorectal adenocarcinoma.
ten Kate J; van den Ingh HF; Khan PM; Bosman FT
Int J Cancer; 1986 Apr; 37(4):479-85. PubMed ID: 3957458
[TBL] [Abstract][Full Text] [Related]
8. Plasma carcinoembryonic antigen concentrations and immunohistochemical patterns of epithelial marker antigens in patients with large bowel carcinoma.
Rognum T; Elgjo K; Brandtzaeg P; Orjasaeter H; Bergan A
J Clin Pathol; 1982 Sep; 35(9):922-33. PubMed ID: 6749906
[TBL] [Abstract][Full Text] [Related]
9. Immunoperoxidase study of the secretory immunoglobulin system in colonic neoplasia.
Isaacson P
J Clin Pathol; 1982 Jan; 35(1):14-25. PubMed ID: 6801094
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of secretory component by colonic neoplasms.
Poger ME; Hirsch BR; Lamm ME
Am J Pathol; 1976 Feb; 82(2):327-38. PubMed ID: 175662
[TBL] [Abstract][Full Text] [Related]
11. [Immunoreactivity in colorectal cancer. Approaches for an immunologic diagnosis?].
Muhrer KH; Kahle M; Pasurka B
Schweiz Med Wochenschr; 1983 Apr; 113(15):546-7. PubMed ID: 6857208
[TBL] [Abstract][Full Text] [Related]
12. Characterization of epitopes of human secretory component on free secretory component, secretory IgA, and membrane-associated secretory component.
Woodard CS; Splawski JB; Goldblum RM; Denney RM
J Immunol; 1984 Oct; 133(4):2116-25. PubMed ID: 6206152
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of the binding of human IgM to secretory component present in normal adult colon epithelia, but not in colon cancer and fetal colon epithelia.
Ditzel H; Erb K; Teisner B; Nielsen B; Borup-Christensen P; Jensenius JC
Histochemistry; 1990; 94(1):95-9. PubMed ID: 2112519
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibody (1116 NS 19-9) defined monosialoganglioside (GICA) in colorectal carcinoma in relation to stage, histopathology and DNA flow cytometry.
Arends JW; Wiggers T; Schutte B; Thijs CT; Verstijnen C; Hilgers J; Blijham GH; Bosman FT
Int J Cancer; 1983 Sep; 32(3):289-93. PubMed ID: 6885183
[TBL] [Abstract][Full Text] [Related]
15. Presence of a sarcomatous component outside the ovary is an adverse prognostic factor for primary ovarian malignant mixed mesodermal/mullerian tumors: a clinicopathologic study of 47 cases.
Kunkel J; Peng Y; Tao Y; Krigman H; Cao D
Am J Surg Pathol; 2012 Jun; 36(6):831-7. PubMed ID: 22588065
[TBL] [Abstract][Full Text] [Related]
16. Immunoglobulins intrinsic to colorectal carcinoma: an unfavorable prognostic association with IgM.
Jones SL; Pihl E; Cuthbertson AM; Hughes ES; Johnson WR; Rollo AJ
J Natl Cancer Inst; 1983 Sep; 71(3):469-72. PubMed ID: 6577222
[TBL] [Abstract][Full Text] [Related]
17. Syncytin immunoreactivity in colorectal cancer: potential prognostic impact.
Larsen JM; Christensen IJ; Nielsen HJ; Hansen U; Bjerregaard B; Talts JF; Larsson LI
Cancer Lett; 2009 Jul; 280(1):44-9. PubMed ID: 19327884
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of secretory component by human colon cancer cells.
Huang SW; Fogh J; Hong R
Scand J Immunol; 1976; 5(3):263-8. PubMed ID: 1273516
[TBL] [Abstract][Full Text] [Related]
19. The potential role of TGFbeta1, TGFbeta2 and TGFbeta3 protein expression in colorectal carcinomas. Correlation with classic histopathologic factors and patient survival.
Tsamandas AC; Kardamakis D; Ravazoula P; Zolota V; Salakou S; Tepetes K; Kalogeropoulou C; Tsota I; Kourelis T; Makatsoris T; Karavias D; Scopa CD; Bonikos DS; Kalofonos HP; Petsas T
Strahlenther Onkol; 2004 Apr; 180(4):201-8. PubMed ID: 15057430
[TBL] [Abstract][Full Text] [Related]
20. Antibody production to secretory component (SC) using recombinant SC fragment.
Kamei M; Iwase T; Krajci P; Brandtzaeg P; Moro I
Adv Exp Med Biol; 1995; 371A():633-5. PubMed ID: 8526006
[No Abstract] [Full Text] [Related]
[Next] [New Search]
